<?xml version="1.0" encoding="UTF-8" ?>
<modsCollection xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" xmlns:slims="http://senayan.diknas.go.id" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd">
<mods version="3.3" ID="2247">
<titleInfo>
<title>Jurnal Farmasi dan Ilmu Kefarmasian Indonesia (JFIKI) Vol. 12 No. 2 (2025)</title>
</titleInfo>
<typeOfResource manuscript="yes" collection="yes">mixed material</typeOfResource>
<genre authority="marcgt">bibliography</genre>
<originInfo>
<place><placeTerm type="text"></placeTerm></place>
<publisher>Universitas Airlangga</publisher>
<dateIssued>2025</dateIssued>
<issuance>monographic</issuance>
<edition>Vol. 12 No. 2 (2025)</edition>
</originInfo>
<language>
<languageTerm type="code">id</languageTerm>
<languageTerm type="text">Indonesia</languageTerm>
</language>
<physicalDescription>
<form authority="gmd">Jurnal</form>
<extent></extent>
</physicalDescription>
<note>Abstract
Background: Patients with atrial fibrillation, venous thromboembolism, valvular disease, cardioembolic stroke, 
and acute myocardial infarction are prescribed the oral anticoagulant warfarin to treat thrombi. To guarantee its 
efficacy and safety, anticoagulants must be closely monitored. Furthermore, warfarin has a narrow therapeutic 
index, which increases the risk of side effects, particularly in the early stages of treatment. Objective: This study 
aimed to analyze the incidence of warfarin side effects in outpatients at Dr. Soetomo General Hospital. Methods: 
A retrospective cross-sectional design was adopted for outpatients at the Cardiology Department of Dr. Soetomo 
General Hospital from March to May 2023. Data were collected on the incidence of side effects in outpatients who 
received warfarin for a minimum of one month through an interview process. Other data, including age, sex, 
duration of warfarin therapy, comorbidities, and INR at the last scan, were extracted from medical records. The 
Chi-Square test was used to examine the data. Results: The results showed that 88 patients (42.7%) had side effects 
of bleeding (126 events). These included gum bleeding (22.3%), hematoma (20.4%), melena (7.7%), 
menometrorrhagia (2.4%), epistaxis (1.9%), hematuria (1.5%), hematemesis (1.0%), hemoptysis (1.0%), 
spontaneous venous bleeding (1.0%), hematochezia (0.5%), hemostasis during blood sampling (0.5%), tongue 
bleeding (0.5%), and subconjunctival bleeding (0.5%). Conclusion: The incidence of side effects during warfarin 
treatment was high, accounting for approximately 42.7% of cases. Furthermore, one patient experienced more 
than one side effect.

Keywords: outpatients, side effects, warfarin</note>
<subject authority=""><topic>warfarin</topic></subject>
<subject authority=""><topic>side effects</topic></subject>
<subject authority=""><topic>outpatients</topic></subject>
<classification></classification><identifier type="isbn"></identifier><location>
<physicalLocation>PERPUSTAKAAN SEKOLAH TINGGI ILMU KESEHATAN SAMARINDA REPOSITORY</physicalLocation>
<shelfLocator></shelfLocator>
<holdingSimple>
<copyInformation>
<numerationAndChronology type="1">JN0419</numerationAndChronology>
<sublocation>Perpus.Akfarsam (Jurnal Nasional Farmasi)</sublocation>
<shelfLocator>051 FAK j</shelfLocator>
</copyInformation>
</holdingSimple>
</location>
<recordInfo>
<recordIdentifier>2247</recordIdentifier>
<recordCreationDate encoding="w3cdtf">2026-02-23 08:55:33</recordCreationDate>
<recordChangeDate encoding="w3cdtf">2026-02-23 09:20:25</recordChangeDate>
<recordOrigin>machine generated</recordOrigin>
</recordInfo></mods></modsCollection>